SPECT/CT PROSTASCINT imaging guides prostate cancer therapy

11/4/2009 | Reuters

SPECT/CT images of PROSTASCINT, a monoclonal antibody attached to the radioisotope Indium-111 for specific targeting of prostate-specific membrane antigen, helped identify areas that needed increased doses of radioactive seeds in patients at risk for metastatic prostate cancer. The images also helped in evaluating for biochemical disease-free survival by showing the presence or absence of lymph node metastases.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN